Form 4: Aclaris Therapeutics Director William Humphries Reports Stock Transaction
SEC Form 4 Filing
Director William Humphries of Aclaris Therapeutics, Inc. reports the vesting of restricted stock units and subsequent ownership of common stock.
Summary
- On June 1, 2024, William Humphries, a director of Aclaris Therapeutics, Inc., reported a transaction involving restricted stock units.
- 4,660 restricted stock units vested, each representing a contingent right to receive one share of common stock.
- Following the transaction, Humphries directly owns 28,732 shares of Aclaris Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects a change in the beneficial ownership of a director.
Key Dates
| Date | Description |
|---|---|
| 05/16/2024 | Date of Power of Attorney execution. |
| 06/01/2024 | Date of transaction involving restricted stock units vesting. |
| 06/04/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.